biostudies-literatureUnknown18Ben Khaled N<h4>Background</h4>Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy.<h4>Objectives</h4>The MONTBLANC study presents a novel investigational strategy utilizing triple immunotherapy through the combination of the anti-programmed cell death ligand 1 antibody durvalumab, the anti-cytotoxic T-lymphocyte-associated antigen-4 tremelimumab, and the anti-vascular endothelial growth factor bevacizumab in patients with aHCC.<h4>Methods and analysis</h4>This randomized, open-label, phase II clinical trial examines two distinct therapeutic regimens through parallel study armTherapeutic advances in medical oncology17588359261417640https://www.ebi.ac.uk/biostudies/studies/S-EPMC12925018biostudies-literatureSequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).PMC12925018Chater JWeinmann AMasi GBen Khaled NAuriemma ASchwald IBeyer GVivaldi CPerkhofer LGeier AWeiss LKubisch IOehrle BEhmer UGonzalez-Carmona MABauer Uvon Felden JMayerle JDe Rosa ARicke JBasch MAntonuzzo LSchneider JSPiseddu IFoerster FZhou THuwer TDe Toni ENSeidensticker MDaniele BEnssle SAltenhofer JOndrejkova KReiter FPEttrich TJSchulze KPhilipp AGroper MNSolda CKarin MfalseSequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).<h4>Background</h4>Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy.<h4>Objectives</h4>The MONTBLANC study presents a novel investigational strategy utilizing triple immunotherapy through the combination of the anti-programmed cell death ligand 1 antibody durvalumab, the anti-cytotoxic T-lymphocyte-associated antigen-4 tremelimumab, and the anti-vascular endothelial growth factor bevacizumab in patients with aHCC.<h4>Methods and analysis</h4>This randomized, open-label, phase II clinical trial examines two distinct therapeutic regimens through parallel study arm2026-01-01T00:00:00Z20262026-07-16T18:47:48.355Z2026-07-12T03:07:54.199ZS-EPMC129250184173265810.1177/17588359261417640